S-Space College of Medicine/School of Medicine (의과대학/대학원) Dept. of Medicine (의학과) The Seoul Journal of Medicine The Seoul Journal of Medicine Vol. 28 No.4 (1987)
Chemosensitivity Testing of Gynecologic Tumors to Chemotherapeutic Agents by the Subrenal Capsule Tumor Implant Assay
신피막하 종양이식 분석법에 의한 부인과 악성종양의 화학감수성 검사에 관한 연구
- Kang, Soon Beam; Kim, Seung Cheal; Chung, Dong Geun; Lee, Hyo Pyo; Shin, Myon Woo
- Issue Date
- Seoul J Med, Vol.28 No.4, pp. 339-346
- Subrenal capsule assay; in vivo test; Gynecologic malignancies; Predictive assay; Chemosensitivity
- Subrenal capsule assay (SRCA) is a promising method of "in vivo" chemosensitivity
test. We planned the laboratory procedure of SRCA in order to make an animal
model of in vivo chemosensitivity test which can be used for the gynecologic cancers.
The 6-day subrenal capsule assays were performed with several gynecologic malignancies.
Fresh tumor fragments of cervical cancer, ovarian cancer, endometrial cancer, sarcoma, and
choriocarcinoma were implanted as 1 X 1 X 1 mm fragments under the renal capsule of
immunocompetent female adult mice and tested against several chemotherapeutic drugs or
In this study, we could show the variations in growth rates of the xenografts under the renal
capsule. This fact seems to reflect the differences of the growth potentials as well as the
heterogeneity of the cell population comprising each human tumor. An average of 69.3% of
tumors showed positive growth and 10.6% demonstrated no measurable change, but 20.0%
showed partial regression in size. The evaluable assay rate of this study was over 90.5%.
The response rates of 19 cervical carcinomas, 2 ovarian carcinomas, 1 endometrial carcinoma,
1 sarcoma, and 1 choriocarcinoma to several chemotherapeutic agents and their combinations
were determined. Response rates varied from 0% (0/3) to adriamycin to 85.7% (617) to
epirubicin plus cis-platin in cervical carcinoma (cf: 75.0% (9/12) to cis-platin, 42.9% (317)
to cyclophosphamide, 40.0% (4/10) to 5-fluorouracil, and 66.7% (4/6) to bleomycin).
A total of 13 clinical correlations of SRCA with clinical outcome were possible in the
prospective study, and the overall predictive accuracy of the SRCA in our study was 84.6%.
The SRCA is considered as a reliable in vivo clinical test to predict the effectiveness of
drugs against a tumor in an individual patient.